Targeting hypothalamic-pituitary-adrenal axis hormones and sex steroids for improving cognition in major mood disorders and schizophrenia: a systematic review and narrative synthesis

@article{Soria2018TargetingHA,
  title={Targeting hypothalamic-pituitary-adrenal axis hormones and sex steroids for improving cognition in major mood disorders and schizophrenia: a systematic review and narrative synthesis},
  author={Virginia Soria and Alexandre Gonz{\'a}lez-Rodr{\'i}guez and Elena Huerta-Ramos and Judith Usall and Jes{\'u}s Cobo and Miquel Bioque and Juan David Barbero and Clemente Garc{\'i}a-Rizo and Meritxell Tost and Jos{\'e} Antonio Monreal and Javier Labad},
  journal={Psychoneuroendocrinology},
  year={2018},
  volume={93},
  pages={8-19}
}
Targeting Hormones for Improving Cognition in Major Mood Disorders and Schizophrenia: Thyroid Hormones and Prolactin
TLDR
Thyroid hormones and prolactin-lowering drugs (e.g. cabergoline, aripiprazole) are candidate drugs to be tested in repurposing clinical trials aiming to improve the cognitive abilities of patients with major mood disorder and schizophrenia.
Hypothalamic-pituitary-adrenal axis-related genes and cognition in major mood disorders and schizophrenia: a systematic review
The relationship between immune and cognitive dysfunction in mood and psychotic disorder: a systematic review and a meta-analysis
TLDR
There is evidence of only a weak association between blood-based immune markers and cognition in mood and psychotic disorders and significant publication and reporting biases were observed and most likely underlie the inflation of such associations in individual studies.
Functional Status of Hypothalamic–Pituitary–Thyroid and Hypothalamic–Pituitary–Adrenal Axes in Hospitalized Schizophrenics in Shanghai
TLDR
Investigation of the neuroendocrinal pathophysiology and its correlation with clinical symptoms in patients with schizophrenia found decreased TT3 and TT4 and elevated ACTH and COR levels appear to be associated with schizophrenia symptoms.
HPA Axis in the Pathomechanism of Depression and Schizophrenia: New Therapeutic Strategies Based on Its Participation
TLDR
New therapeutic strategies that affect the HPA axis, such as glucocorticoid receptor (GR) antagonists, vasopressin V1B receptor antagonists and non-psychoactive CB1 receptor agonists in depression and/or schizophrenia are discussed.
Corticosteroid-induced psychiatric disorders: genetic studies are needed
  • F. Thibaut
  • Psychology, Medicine
    European Archives of Psychiatry and Clinical Neuroscience
  • 2019
TLDR
Despite their well-known potent anti-inflammatory and immuno-suppressant properties in many medical conditions, corticosteroid treatments are often associated with neuropsychiatric complications, which remain poorly understood.
Is the HPA Axis as Target for Depression Outdated, or Is There a New Hope?
TLDR
This review will cover tests detecting altered HPA axis function and the specific treatment options such as glucocorticoid receptor (GR) antagonists, corticotropin-releasing hormone 1 (CRH1) receptor antagonists, tryptophan 2,3-dioxygenase (TDO) inhibitors and FK506 binding protein 5 (FKBP5) receptors antagonists.
Sex differences in the hypothalamic–pituitary–adrenal axis: An obstacle to antidepressant drug development?
TLDR
It is suggested that clinical testing of HPA axis‐related compounds creates an opportunity for targeted, personalized antidepressant treatments based on sex, and that sex differences contribute to the failure of novel H PA axis‐based drugs in clinical trials.
Women Undergoing Hormonal Treatments for Infertility: A Systematic Review on Psychopathology and Newly Diagnosed Mood and Psychotic Disorders
TLDR
It is suggested that protocols without gonadotropin stimulation show a better mood profile when compared to those using GnRH antagonists or GnRH agonists, and that patients with major mood and psychotic disorders need to be included in future studies.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 131 REFERENCES
A systematic review of hypothalamic-pituitary-adrenal axis function in schizophrenia: implications for mortality.
TLDR
The evidence suggests people with schizophrenia can experience both hyper- and hypo-function of the HPA axis, and it is likely that this contributes to the pattern of poor physical health and premature mortality suffered byPeople with schizophrenia, in particular the high rates of cardiovascular and metabolic disturbance.
Cognitive dysfunction in major depression and bipolar disorder: Assessment and treatment options
TLDR
There is a paucity of high‐quality trials examining either pharmacological or non‐pharmacological modes of intervention in patients with mood disorders, and clinicians are increasingly targeting cognitive symptoms as part of comprehensive treatment strategies.
Changes in Brain-Derived Neurotrophic Factor Following Treatment with Mifepristone in Bipolar Disorder and Schizophrenia
TLDR
Differing BDNF responses to increasing cortisol levels between patients with schizophrenia and with bipolar disorder may reflect underlying pathophysiological mechanisms.
The HPA axis in bipolar disorder: Systematic review and meta-analysis
Improvements in Neurocognitive Function and Mood Following Adjunctive Treatment with Mifepristone (RU-486) in Bipolar Disorder
TLDR
Evidence is provided that glucocorticoid receptor antagonists may have useful cognitive-enhancing and possibly antidepressant properties in bipolar disorder and selective improvement in neurocognitive functioning was observed following treatment with mifepristone.
...
1
2
3
4
5
...